We work at the interface of discovery science and clinical translation to understand the biological processes that promote health and how these pathways go wrong in disease.
Our researchers work collaboratively across teams to adopt a multidisciplinary approach, enabled by our world-class technology platforms, and through strategic partnerships with other basic and clinical research centres in Oxford, across the UK, and internationally.
Our research falls broadly within the thematic areas of immunity and microbiome, inflammation biology and tissue remodelling and regeneration and is relevant for a range of chronic inflammatory diseases including arthritis, inflammatory bowel disease and certain types of cancer. Clinical translation is a cross-cutting theme across the Institute, as we aim to harness our discovery research to guide the development of new diagnostics and therapeutics.
Technology Platforms and Centres
We have built a number of platforms and centres that offer access to state-of-the-art technologies to enable transformative research, supported by the Kennedy Trust for Rheumatology Research. These initiatives create a focal point for technology innovation and collaboration to extend the reach and impact our work.
Cell Dynamics Platform
The Cell Dynamics Platform offers cutting-edge technologies and know-how to visualise and explore the dynamics of cellular responses across scales - from single molecules in cells, to cellular activation in tissues and cellular networks in disease. Led by Professor Michael Dustin, the platform encompasses capabilities in advanced imaging and microscopy, mass cytometry and flow cytometry, and involves collaboration with numerous other research centres, including the Rosalind Franklin Institute in Harwell.
Oxford Centre for Microbiome Studies
The Oxford Centre for Microbiome Studies provides an experimental pipeline to understand how the microbes in our bodies impact health and disease. The Centre links eight University Departments, with oversight from Dr Jethro Johnson and Professor Fiona Powrie, and brings together approaches in computational biology, advanced microbial cultivation, gnotobiotic and germ-free systems, metabolomics and immunology for both descriptive and functional microbiome analysis.
Data Science Platform
We have built a strong core of technologies and expertise in single-cell genomics, statistical genetics, microbial genomics and computational biology, together with a facility for the curation and warehousing of meta-data to integrate experimental and clinical data sets. The platform supports analysis of both disease models and large patient cohorts for discovery and understanding of the molecular pathways that drive disease onset or predict outcomes. Academic oversight of the platform is provided by Dr Stephen Sansom, Dr Brian Marsden and Professor Irina Udalova in collaboration with other investigators working in the area.
The Arthritis Therapy Acceleration Programme, led by Professor Christopher Buckley, was launched in 2017 to facilitate experimental medicine studies, including early-phase clinical trials, in immune-mediated inflammatory disease. This collaboration between the Universities of Birmingham and Oxford includes a partnership with seven NHS Trusts to juxtapose cutting-edge research with clinical expertise, while providing crucial access to over 7 million patients.
A-TAP complements various other strategic programmes at the Institute for clinical translational including the Centre for Osteoarthritis Pathogenesis, funded by Versus Arthritis and directed by Professor Tonia Vincent.